Investor Relations

Advanced therapies for the sports medicine and severe burn care markets

Day High:
Day Low:
Volume:
on
Copyright West LLC. Minimum 15 minutes delayed.

Investor Relations

Press Releases

January 10, 2023

Vericel Announces Preliminary Fourth-Quarter and Full-Year 2022 Financial Results and Accelerated Launch Timeline for MACI Arthroscopic Program

January 4, 2023

Vericel to Present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023

December 29, 2022

Vericel Announces FDA Approval of NexoBrid for the Treatment of Severe Thermal Burns in Adults

Events and Presentations

Upcoming Events
More events are coming soon.

 

 

Presentations

Quarterly Results

Show all

Stock Quote & Analyst Coverage

Stock Quote ()

Change
Volume
Today's Open
Previous Close
Today's High
Today's Low
52 Week High
52 Week Low
Vericel Corporation is covered by the following analysts.
Ryan Zimmerman
BTIG
Swayampakula Ramakanth
H.C. Wainwright & Co.
Jeff Cohen
Ladenburg Thalmann
Danielle Antalffy
LEERINK
George Sellers
Stephens
Samuel Brodovsky
Truist

Vericel Corporation is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Vericel Corporation's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Vericel Corporation or its management. Vericel Corporation does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.